These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35317190)

  • 41. Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose.
    Zhao D; Wang X; Liu J; Au C; Basavaraj V; Sri CD; Nikolenko VN; Beeraka NM; Shivaprakash P; Fan R
    Curr Pharm Biotechnol; 2023; 24(13):1603-1612. PubMed ID: 36843370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
    He X; He C; Hong W; Yang J; Wei X
    Med Res Rev; 2023 Jul; 43(4):932-971. PubMed ID: 36929527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern.
    Cao L; Guo J; Li H; Ren H; Xiao K; Zhang Y; Zhu S; Song Y; Zhao W; Wu D; Chen Z; Zhang Y; Xia B; Ji T; Yan D; Wang D; Yang Q; Zhou Y; Li X; Hou Z; Xu W
    Microbiol Spectr; 2023 Feb; 11(2):e0268722. PubMed ID: 36847495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.
    Khatri R; Siddqui G; Sadhu S; Maithil V; Vishwakarma P; Lohiya B; Goswami A; Ahmed S; Awasthi A; Samal S
    Med Microbiol Immunol; 2023 Feb; 212(1):103-122. PubMed ID: 36583790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.
    Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
    Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-COV-2 Variants: Differences and Potential of Immune Evasion.
    Hirabara SM; Serdan TDA; Gorjao R; Masi LN; Pithon-Curi TC; Covas DT; Curi R; Durigon EL
    Front Cell Infect Microbiol; 2021; 11():781429. PubMed ID: 35118007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2 Omicron variant: Characteristics and prevention.
    He X; Hong W; Pan X; Lu G; Wei X
    MedComm (2020); 2021 Dec; 2(4):838-845. PubMed ID: 34957469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
    Alam MS
    Heliyon; 2023 Feb; 9(2):e13285. PubMed ID: 36744070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Covid-19 variants: Impact on transmissibility and virulence.
    Malik YA
    Malays J Pathol; 2022 Dec; 44(3):387-396. PubMed ID: 36591708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
    Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
    Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2.
    Peng Q; Zhou R; Liu N; Wang H; Xu H; Zhao M; Yang D; Au KK; Huang H; Liu L; Chen Z
    Cell Mol Immunol; 2022 Nov; 19(11):1302-1310. PubMed ID: 36224497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
    Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
    Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
    Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.